Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Significant progress has been made in the understanding of lung cancer biology, due in
large part to advancement in the understanding of tumor biology and pathogenesis …

Immunotherapy has prompted a paradigm shift in advanced non-small cell lung cancer
(NSCLC) treatment, by demonstrating superior efficacy to chemotherapy alone both in …

Cancer immunotherapy (CIT) has transformed cancer treatment. In particular,
immunotherapies targeting the programmed death ligand 1 (PD-L1)/programmed death 1 …

PI3K/Akt signaling is activated in cancers and governs tumor initiation and progression, but
how Akt is activated under diverse stresses is poorly understood. Here we identify AMPK as …

Both the first‐generation reversible epidermal growth factor receptor (EGFR) inhibitors
gefitinib and erlotinib and the second‐generation covalent epidermal growth factor receptor …

The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1)
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …

Lung cancer is the leading cause of cancer death in the world and there is no current
treatment able to efficiently treat the disease as the tumor is often diagnosed at an advanced …

Lung cancer is the most common cancer worldwide. Up to 85% of lung cancer cases are
diagnosed as non-small cell lung cancer (NSCLC). The effectiveness of NSCLC treatment is …

Radiation sensitizers that can selectively act on cancer cells hold great promise to patients
who receive radiation therapy. We developed a novel targeted therapy and radiation …